ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "physical function"

  • Abstract Number: 1293 • ACR Convergence 2023

    Single Camera Hand Motion Capturing as a Digital Biomarker for Disease Activity in Rheumatoid Arthritis Using Computer Vision: The Proof-of-Concept MeFisto Study

    Vincenzo Venerito1, Tobias Maningold2, Deborah Markham3, Marc Blanchard4, Florenzo Iannone1 and Thomas Hügle5, 1Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, 2Department of Rheumatology, University Hospital Bern (Inselspital), University Bern, Bern, Switzerland, 3on behalf of Department Rheumatology, University Hospital Lausanne, Lausanne, Switzerland, 4Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University Lausanne, Lausanne, Switzerland, 5Dept. of Rheumatology, University Hospital Lausanne (CHUV) and University of Lausanne, Lausanne, Switzerland

    Background/Purpose: Computer vision technology offerspromising possibilities for remotely assessing disease activity in rheumatoid arthritis (RA) patients, enabling telemedicine and improving access to care. The objective…
  • Abstract Number: 0207 • ACR Convergence 2022

    Novel Digital Technologies for the Assessment of Objective Measures and PROs in Patients with Rheumatoid Arthritis: A Pilot Study Using Smart Devices and a Bespoke Mobile App

    Valentin Hamy1, Christopher Llop2, Christopher W Yee2, Luis Garcia-Gancedo3, Aoife Maxwell4, Wen-Hung Chen5, Ryan Tomlinson3, Priyanka Bobbili2, Julien Bendelac2, Jessica Landry2, Maral DerSarkissian6, Mihran Yenikomshian2, Elinor A Mody7, Mei Sheng Duh2 and Rachel Williams3, 1GlaxoSmithKline, London, United Kingdom, 2Analysis Group Inc, Boston, MA, 3GlaxoSmithKline, Philadephia, 4GlaxoSmithKline, Stevenage, United Kingdom, 5GlaxoSmithKline, Value Evidence and Outcomes, Philadephia, 6Analysis Group Inc, Los Angeles, CA, 7Reliant Medical Group, Worcester, MA

    Background/Purpose: RA symptoms are typically only assessed intermittently in clinical practice and clinical trials. Digital technologies (wearables, smartphones) can facilitate continuous remote monitoring of patients'…
  • Abstract Number: 2118 • ACR Convergence 2022

    Achieving Increasingly Stringent Clinical Disease Control Criteria Is Associated with Greater Improvements in Patient-Centric Measures of Physical Function and Pain in Patients with Active PsA: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    Jessica Walsh1, Laura Coates2, Philip J Mease3, Joseph Merola4, Peter Nash5, Alexis Ogdie6, William Tillett7, Paolo Gisondi8, Barbara Ink9, Deepak Assudani9, Rajan Bajracharya9, Jérémy Lambert10, Vanessa Taieb11, Damon Willems12 and Lars Erik13, 1University of Utah, Salt Lake City, UT, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 5School of Medicine, Griffith University, Sunshine Coast, Australia, 6Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 7Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 8Dermatology and Venereology, Department of Medicine, Università di Verona, Verona, Italy, Verona, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Colombes, France, Irigny, France, 11UCB Pharma, Colombes, France, 12UCB Pharma, Brussels, Belgium, 13Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark

    Background/Purpose: Examine the association between achieving increasingly stringent clinical disease control criteria and patient-centric measures of physical function and pain in patients with PsA, using…
  • Abstract Number: 0410 • ACR Convergence 2022

    Achieving Increasingly Stringent Clinical Response Criteria & Lower Levels of Disease Activity Is Associated with Greater Improvements in Physical Function & HRQoL in Patients with Active Axial Spondyloarthritis: 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies

    Marina Magrey1, Atul Deodhar2, Philip J Mease3, Victoria Navarro-Compán4, Sofia Ramiro5, Martin Rudwaleit6, Christine de la Loge7, Carmen Fleurinck8, Vanessa Taieb9, Michael Frank Mørup10, Marga Oortgiesen11 and Jonathan Kay12, 1Case Western Reserve University, University Hospitals, Richfield, OH, 2Oregon Health & Science University, Portland, OR, USA, Portland, OR, 3Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, 4Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 5Leiden University Medical Center, Leiden, Netherlands, 6University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, 7UCB Pharma, Brussels, Belgium, 8UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 9UCB Pharma, Colombes, France, 10UCB Pharma, Copenhagen, Denmark, 11UCB Pharma, Raleigh, NC, 12Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA

    Background/Purpose: Examine the association between achieving increasingly stringent clinical response criteria and lower levels of disease activity, and improvements in physical function and health-related quality…
  • Abstract Number: 2239 • ACR Convergence 2022

    Effect of Treatment with IVIG (octagam10%) on Skin Symptoms and Quality of Life in Subjects with Dermatomyositis. Results of a Large, Randomized, Placebo-controlled International Phase III Trial

    Rohit Aggarwal1, Christina Charles-Schoeman2, joachim Schessl3, Victoria Werth4, Zsuzsanna Bata-Csorgo5, Mazen Dimachkie6, Zoltan Griger7, Sergey Moiseev8, Chester Oddis9, Elena Schiopu10, Jiří Vencovský11, Irene Beckmann12, Elisabeth Clodi13, Todd Levine14 and and the ProDERM investigators15, 1Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, 2Division of Rheumatology, University of California, Los Angeles, Santa Monica, CA, 3Friedrich-Baur-Institut/Medical University Munich, Mainkofen, Germany, 4Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, 5University of Szeged, Faculty of Medicine, Szeged, Hungary, 6University of Kansas Medical Center, Kansas City, KS, 7University of Debrecen, Debrecen, Hungary, 8First Moscow State Medical University, Moscow, Russia, 9University of Pittsburgh, Pittsburgh, PA, 10Michigan Medicine Rheumatology Clinic – Taubman Center, Ann Arbor, MI, 11Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 12Octapharma PharmazeutikaProduktionsGesmbH, Vienna, Austria, 13Octapharma Pharmazeutika ProduktionsgesmbH, Vienna, Austria, 14Phoenix Neurological Associates, Ltd., Phoenix, AZ, 15Institutions in Europe and North America, Vienna, Austria

    Background/Purpose: Dermatomyositis (DM) is a rare chronic systemic autoimmune disease with characteristic skin rashes and progressive proximal muscle weakness. The efficacy of IVIg treatment in…
  • Abstract Number: 0412 • ACR Convergence 2022

    Bimekizumab Improves Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies

    Maureen Dubreuil1, Karl Gaffney2, Lianne Gensler3, Jonathan Kay4, Victoria Navarro-Compán5, Christine de la Loge6, Alicia Ellis7, Carmen Fleurinck8, Marga Oortgiesen9, Vanessa Taieb10 and Atul Deodhar11, 1Department of Rheumatology, Boston University School of Medicine, Boston, MA, 2Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, 3Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 4Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, 5Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, 6UCB Pharma, Brussels, Belgium, 7UCB Pharma, Raleigh, 8UCB Pharma, Brussels, Belgium, Oosterzele, Belgium, 9UCB Pharma, Raleigh, NC, 10UCB Pharma, Colombes, France, 11Oregon Health & Science University, Portland, OR, USA, Portland, OR

    Background/Purpose: Axial spondyloarthritis (axSpA) severely impacts patients' (pts) physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively…
  • Abstract Number: 0503 • ACR Convergence 2022

    The Effect of Social Isolation on 1-Year Outcomes After Surgical Repair of Low Trauma Hip Fracture

    Robyn Lipschultz1, Dina Sheira1, Marianna Frey2, Mangala Rajan3, Joseph Lane1 and Lisa Mandl1, 1Hospital for Special Surgery, New York, NY, 2University of Rochester School of Medicine and Dentistry, New York, NY, 3Weill Cornell Medicine, New York, NY

    Background/Purpose: Hip fractures are a serious public health issue with a significant population burden, especially among those over 65 years old. Social isolation—how integrated a…
  • Abstract Number: 0553 • ACR Convergence 2022

    Stair Climbing Difficulty and Risk of Functional Limitation in Knee Osteoarthritis: A Simple Functional Vital Sign?

    Jason Jakiela1, Dana Voinier1, Yvonne Golightly2, Jennifer Horney1, Thomas Bye1, Jéssica Bianca Aily1 and Daniel White1, 1University of Delaware, Newark, DE, 2University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Knee osteoarthritis (OA) is a leading cause of functional limitation in older adults, and difficulty with climbing stairs is often the first-reported limitation. As…
  • Abstract Number: 0739 • ACR Convergence 2022

    Effect of Tailored Self-Management Interventions on Health Outcomes in Individuals with Chronic Musculoskeletal Conditions

    Ellen Wang1, Isabel Rodrigues2 and Linda Li3, 1University of British Columbia, Arthritis Research Canada, Vancouver, BC, Canada, 2McMaster University, GERAS Centre for Aging Research, Hamilton, ON, Canada, 3University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Self-management, has been recognized as an essential component of successful chronic musculoskeletal (MSK) management; yet existing reviews of self-management interventions have found only modest…
  • Abstract Number: 0851 • ACR Convergence 2022

    Responsiveness of Patient-Reported Physical Function Measures in Juvenile Arthritis

    Alysha Taxter1, Laura Schanberg2, Marc Natter3 and for the CARRA Registry investigators4, 1Nationwide Children's Hospital, Columbus, OH, 2Duke University Medical Center, Durham, NC, 3Boston Children's Hospital, Boston, MA, 4CARRA, Washington, DC

    Background/Purpose: The ACR Pediatric Criteria (ACR Pedi) contains a core set of outcome variables, including a measure of functional ability, to evaluate improvement over time…
  • Abstract Number: 0899 • ACR Convergence 2022

    Performance of the Foot Function Index Questionnaire in Patients with Rheumatoid Arthritis

    Joan Manuel Dapeña, Lucia Alascio, Eliana Rebeca Serrano, Juan Manuel Bande, Maria Alejandra Medina, Diana Silvia Klajn, Jose Angel Caracciolo and Silvia Beatriz Papasidero, Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina

    Background/Purpose: Multiple questionnaires and objective assessment tools have been developed to determine functional compromise in Rheumatoid Arthritis (RA). One of the most used tools to…
  • Abstract Number: 1198 • ACR Convergence 2022

    Validation of Remote Physical Performance and Cognitive Functioning Measures Among Individuals with Systemic Lupus Erythematosus

    Courtney Hoge1, C. Barrett Bowling2, Charmayne Dunlop-Thomas1, Bradley Pearce1, S. Sam Lim1, Cristina Drenkard1 and Laura Plantinga1, 1Emory University, Atlanta, GA, 2Duke University, Durham, NC

    Background/Purpose: The disruption of the COVID-19 pandemic presented an opportunity for researchers to develop and administer remote versions of measures for ongoing studies. In an…
  • Abstract Number: 1307 • ACR Convergence 2022

    Effect of Romosozumab in Postmenopausal Women with Knee Osteoarthritis: Results from the FRAME Clinical Trial

    Nancy Lane1, Donald Betah2, Cynthia Deignan2, Mary Oates2, Zhenxun Wang2, Jen Timoshenko3, Aliya Khan4 and Neil Binkley5, 1University of California Davis, Hillsborough, CA, 2Amgen, Inc., Thousand Oaks, CA, 3UCB Pharma, Slough, United Kingdom, 4McMaster University, Oakville, ON, Canada, 5University of Wisconsin, Madison, WI

    Background/Purpose: Osteoarthritis (OA) and osteoporosis (OP) often occur concomitantly in the elderly. The relationship between OA and OP is complex, with increased fracture risk reported…
  • Abstract Number: 1491 • ACR Convergence 2022

    Clinically Relevant Differences in the Mobility of Patients with Axial Spondyloarthritis Related to Daytime of Performance

    David Kiefer1, Juergen Braun1, Lucia Schneider1, Niklas Kolle1, Uta Kiltz1, Ioana Andreica2, Philipp Sewerin1, Bjoern Buehring3, susanne herbold1 and Xenofon Baraliakos4, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Rheumazentrum Ruhrgebiet, Ruhr-Universität-Bochum, Herne, Germany, 3Bergisches Rheuma-Zentrum, Velbert, Germany, 4Rheumazentrum Ruhrgebiet Herne, Herne, Germany

    Background/Purpose: Patients with axial spondyloarthritis (axSpA) often experience impairments of spinal mobility and physical function due to inflammation and structural damage. Back pain and morning…
  • Abstract Number: 1507 • ACR Convergence 2022

    Diagnostic Delay of More Than 6 Months Contributes to Poor Patient-Reported Outcome Measures in Psoriatic Arthritis

    Neel Tapryal1, George Gondo2, M. Elaine Husni3, Alice Gottlieb4 and Joseph Merola5, 1Cleveland Clinic, Rocky River, OH, 2National Psoriasis Foundation, Portland, OR, 3Cleveland Clinic, Cleveland, OH, 4Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY, 5Harvard Medical School, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Psoriatic arthritis (PsA) is a type of inflammatory arthritis in which the time between symptom onset and a diagnosis of PsA is highly variable.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology